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 Abstract 
 Background: Oxidative stress and disturbances in serotonergic and dopaminergic neuro-
transmission may play a role in the pathophysiology of delirium.  Aims: In this study, we in-
vestigated levels of amino acids, amino acid ratios and levels of homovanillic acid (HVA) as 
indicators for oxidative stress and disturbances in neurotransmission.  Methods: Plasma lev-
els of amino acids, amino acid ratios and HVA were determined in acutely ill patients aged 
 ≥ 65 years admitted to the wards of Internal Medicine and Geriatrics of the Erasmus Univer-
sity Medical Center and the ward of Geriatrics of the Havenziekenhuis, Rotterdam, The Neth-
erlands. Differences in the biochemical parameters between patients with and without de-
lirium were investigated by analysis of variance in models adjusted for age, gender and 
comorbidities.  Results: Of the 86 patients included, 23 had delirium. In adjusted models, 
higher mean phenylalanine/tyrosine ratios (1.34 vs. 1.14, p = 0.028), lower mean tryptophan/
large neutral amino acids ratios (4.90 vs. 6.12, p = 0.021) and lower mean arginine levels (34.8 
vs. 45.2 μmol/l, p = 0.022) were found in patients with delirium when compared to those with-
out. No differences were found in HVA levels between patients with and without delirium. 
 Conclusion: The findings of this study suggest disturbed serotonergic neurotransmission and 
an increased status of oxidative stress in patients with delirium.  © 2015 S. Karger AG, Basel 
 Published online: December 3, 2015 
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 Introduction 
 Delirium is a common and severe complication among elderly patients and is associated 
with increased morbidity and mortality, prolonged hospital stay, increased risk of post-
discharge institutionalization and dementia  [1, 2] . The pathophysiology of delirium is still 
largely hypothetical. Identifying accurate biomarkers for delirium may shed light on the 
pathophysiology and may help to improve delirium recognition and care.
 Oxidative stress and disturbances in serotonergic and dopaminergic neurotransmission 
might all be involved in the pathophysiology of delirium and probably act together  [3] . 
Within the central nervous system, tetrahydrobiopterin (BH 4 ) functions as an essential 
cofactor in enzymatic reactions responsible for the production of serotonin and dopamine. 
In addition, BH 4 is a cofactor for nitric oxide synthase (NOS) that catalyzes the production 
of nitric oxide (NO) and citrulline from arginine  [4] . If BH 4 becomes limited, this could 
impair serotonin and dopamine synthesis. Besides, when BH 4 is partially deficient, some 
cellular sources of NOS may generate superoxide (O 2 ∙ – ) instead of NO and citrulline  [4, 5] . 
In patients with delirium, BH 4 status has only been investigated after elective cardiac 
surgery  [6] .
 In order to assess BH 4 status, we measured amino acid levels and subsequently calcu-
lated the phenylalanine/tyrosine (Phe/Tyr) ratio. This ratio is an indicator for the BH 4 status 
as it reflects the activity of the enzyme Phe hydroxylase, an enzyme that uses BH 4 as a cofactor 
 [4, 7] . An elevated ratio is suggestive for decreased BH 4 availability. Furthermore, we deter-
mined the ratios of tryptophan (Trp), Phe and Tyr to the other large neutral amino acids 
(LNAAs). Trp is the precursor of serotonin, while Phe and Tyr are the precursors of dopamine. 
The LNAAs (Trp, Phe, Tyr, valine, isoleucine and leucine) compete with each other for 
transport across the blood-brain barrier. Therefore, a decreased Trp/LNAAs ratio is sugges-
tive for a decline in the amount of Trp that enters the brain and consequently for reduced 
synthesis of serotonin  [8] . Moreover, we measured plasma levels of the dopamine metabolite 
homovanillic acid (HVA), approximately 30% of which is estimated to originate from dopa-
mine neurons in the central nervous system and which is therefore thought to be a reliable 
indicator for central dopamine activity  [9] . Finally, we measured plasma levels of arginine 
and citrulline to investigate the production of NO by NOS.
 The aim of the study was to investigate BH 4 status, potential disturbances in serotonergic 
and dopaminergic neurotransmission and the production of NO in patients with and without 
delirium.
 Methods 
 Study Design and Participants 
 The present study was performed within the Delirium In The Old (DITO) study in which 
mean levels of neopterin, interleukin-6 and insulin-like growth factor-1 were compared 
between patients with and without delirium  [10] . In the DITO study, a cross-sectional study, 
we included patients who were admitted to the wards of Internal Medicine and Geriatrics of 
the Erasmus University Medical Center and the ward of Geriatrics of the Havenziekenhuis, 
Rotterdam, The Netherlands. All acutely admitted patients aged  ≥ 65 years were eligible to 
participate. Exclusion criteria were a diagnosis of Lewy body dementia, Parkinson’s disease, 
neuroleptic malignant syndrome, tardive dyskinesia, ongoing treatment with antipsychotics 
or other psychiatric medications except haloperidol and benzodiazepines, aphasia, insuffi-
cient understanding of the Dutch language and a Mini-Mental State Examination (MMSE) 
score <10 points out of 30. We excluded patients with a MMSE <10 because it can be quite 
452Dement Geriatr Cogn Disord Extra 2015;5:450–458
 DOI: 10.1159/000440696 
E X T R A
 Egberts et al.: Disturbed Serotonergic Neurotransmission and Oxidative Stress in 
Elderly Patients with Delirium 
www.karger.com/dee
© 2015 S. Karger AG, Basel
difficult to distinguish between features of severe dementia and delirium at admission as well 
as to measure improvement of cognitive function in this group.
 Written informed consent was obtained from all participants. In case of delirium or 
cognitive impairment at the time of admission, informed consent was obtained from a repre-
sentative of the patient. The Medical Ethics Committee of the Erasmus University Medical 
Center approved the study protocol.
 Procedures 
 All participants were observed daily by the nursing and medical staff and by members of 
the research team until discharge. To screen for a change in behavior, the 13-item Delirium 
Observation Screening scale was used during the first 5 days of admission  [11] . The diagnosis 
of delirium was made by a geriatrician, according to the Diagnostic and Statistical Manual of 
Mental Disorders, 4th edition (DSM-IV)  [12] , and was based on the psychiatric examination 
of the patient, the medical and nursing records, including the Delirium Observation Screening 
scale scores, and information given by the patient’s closest relative. When the diagnosis of 
delirium was doubtful, the case was discussed with the geriatric consultation team to gain 
consensus.
 Demographic and clinical data were collected at admission. Age, gender and living situ-
ation before admission were documented. Cognitive functioning was assessed in absence of 
delirium using the MMSE  [13] . When it was impossible to score the MMSE during admission 
because the patient was too ill, cognitive function was discussed with a clinician or assessed 
with information from the available medical records. When the clinical opinion was that the 
patient would have a MMSE score  ≥ 10, the patient was not excluded from the study. Severity 
of comorbidities was scored using the Charlson Comorbidity Index. This index encompasses 
19 medical conditions, including dementia, and each condition is weighted with a score of 1–6 
by severity  [14] . Physical functionality was assessed using the 6-item Katz Activities of Daily 
Living scale and the Barthel index  [15, 16] . Instrumental functionality was assessed using the 
7-item Older Americans Resource Scale for Instrumental Activities of Daily Living  [15] . Frailty 
was measured with the Identification of Seniors at Risk questionnaire  [17] . Blood samples of 
all patients were collected within 48 h after admission. When a patient developed delirium 
during the hospital stay, new blood samples were collected within 24 h after the onset of the 
delirium and were used instead of the first blood samples for the statistical analyses.
 Biochemical Measurements 
 Non-fasting blood was collected preferably between 8 and 10 a.m. in an 8-ml tube con-
taining ethylene diamine tetraacetic acid. After blood sampling, the tubes were stored at 
room temperature to prevent changes in the transfer of amino acids between plasma and 
blood cells  [18] . Within 3 h, the blood was centrifuged for 20 min at 2,650  g and 20  °  C. The 
obtained plasma was stored at –80 ° C until analysis.
 Plasma amino acid levels were determined by high-performance liquid chromatography 
with automated pre-column derivatization with ortho-phthalaldehyde as previously de-
scribed  [18] . Plasma HVA levels were determined by reversed-phase high-performance liquid 
chromatography and electrochemical detection, as previously described for the determi-
nation of serotonin  [19] .
 Statistical Analysis 
 Medians and interquartile ranges were determined for continuous participant character-
istics and proportions for categorical characteristics. Biochemical parameters with a skewed 
distribution were logarithmically transformed (all amino acids, amino acid ratios and HVA). 
Univariate one-way analysis of variance was used to investigate the association between 
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mean levels of amino acids, amino acid ratios and HVA (dependent variables) and the presence 
of delirium. Models were adjusted for age, gender and the Charlson Comorbidity Index. Addi-
tional analyses were performed for all amino acids, amino acid ratios and HVA after also 
adding MMSE score to the models. A two-tailed p <0.05 was defined as statistically significant.
 Statistical Package for the Social Sciences, version 21.0 (SPSS Inc., Chicago, Ill., USA) was 
used to perform the statistical analyses. GraphPad Prism 5.01 for Windows (GraphPad 
Software, San Diego, Calif., USA) was used to draw all graphs.
 Results 
 Participant Characteristics 
 Table 1 presents the baseline characteristics of the 86 participants who were included in 
the study. Of the 23 patients diagnosed with delirium, 21 were admitted to hospital with 
delirium and 2 developed delirium during admission.
 Analyses of Biochemical Parameters 
 The mean levels and corresponding 95% confidence intervals (CIs) of the investigated 
biochemical parameters in patients with and without delirium are presented in  tables 2 and 
 3 . In adjusted models, mean levels of arginine were significantly lower in patients with 
delirium (34.8 μmol/l, 95% CI 28.8–42.0) than in those without (45.2 μmol/l, 95% CI 40.6–
50.5) (p = 0.022) ( fig. 1 ). Concerning the amino acid ratios, mean Phe/Tyr ratios were signif-
icantly higher in patients with delirium (1.34, 95% CI 1.19–1.51) than in patients without 
delirium (1.14, 95% CI 1.06–1.22) (p = 0.028) ( fig. 1 ). In addition, mean Trp/LNAAs ratios 
were significantly lower in patients with delirium (4.90, 95% CI 4.19–5.74) than in those 
without (6.12, 95% CI 5.58–6.71) (p = 0.021) ( fig. 1 ). No associations between the other 
 Table 1.  Characteristics of the study participants
No delirium (n = 63) Delirium (n = 23)
Male gender 4 7.6% 43.5%
Age, years 81.0 (75.0 – 85.0) 87.0 (84.0 – 88.0)
MMSE scorea 25.5 (22.0 – 28.0)b 20.0 (18.0 – 25.0)c
Living situation
Home 47.6% 26.1%
Home care 31.7% 30.4%
Residential home 7.9% 17.4%
Nursing home 3.2% 13.0%
Missing data 9.5% 13.0%
Katz Activities of Daily Living scored 0.0 (0.0 – 3.0) 2.0 (1.0 – 11.0)
OARS-IADL scoree 5.0 (0.0 – 10.0) 9.5 (3.5 – 14.0)
Barthel indexf 18.0 (13.0 – 20.0) 16.0 (9.5 – 19.0)
Identification of Seniors at Risk scoreg 4.0 (2.0 – 6.0) 6.0 (4.8 – 7.0)
Charlson Comorbidity Indexh 1.0 (1.0 – 2.0) 2.0 (1.0 – 3.0)
 Values are expressed as medians (interquartile ranges) or percentages.
OARS-IADL = Older Americans Resource Scale for Instrumental Activities of Daily Living.
a Range 0 (severe cognitive impairment) to 30 (no cognitive impairment). b Three values missing. c Four 
values missing. d Range 0 (no disability) to 12 (severe disability). e Range 0 (no disability) to 14 (severe 
disability). f Range 0 (severe disability) to 20 (no disability). g Scores ≥2 indicate a high risk of functional 
decline. h Range 0 – 37 (severe burden of comorbidities).
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amino acids and ratios and delirium were found, although citrulline ( fig. 1 ) and Trp levels 
were at the border of significance lower in patients with delirium than in those without (p = 
0.052 and p = 0.067, respectively).
 HVA data were missing for 2 patients (delirium, n = 1 [not enough plasma]; no delirium, 
n = 1 [measurement failed]). Mean HVA levels were not statistically significantly different 
between patients with delirium (123.0 nmol/l, 95% CI 93.3–162.6) and patients without 
delirium (93.3 nmol/l, 95% CI 79.4–109.4) (p = 0.098).
 In the models additionally adjusted for MMSE score, the association between arginine 
and delirium did not reach statistical significance (delirium: mean 36.0 μmol/l, 95% CI 28.7–
45.1 vs. no delirium: mean 44.8 μmol/l, 95% CI 39.8–50.5, p = 0.107). Mean Phe/Tyr ratios 
remained borderline significantly higher in patients with delirium (1.34, 95% CI 1.16–1.55) 
than in those without (1.15, 95% CI 1.07–1.24) (p = 0.089) and mean Trp/LNAAs ratios 
remained borderline significantly lower in patients with delirium (5.00, 95% CI 4.15–6.01) 
compared to those without (6.15, 95% CI 5.58–6.78) (p = 0.062). Estimates for the other 
biochemical parameters remained statistically insignificant (data not shown).
 Table 2. Mean levels of amino acids
No delirium (n = 63) Delirium (n = 23) p value
Glutamic acid, μmol/l 46.2 (40.9 – 52.2) 41.3 (33.5 – 50.9) 0.368
Serine, μmol/l 84.5 (78.7 – 90.8) 81.3 (71.9 – 91.8) 0.596
Glycine, μmol/l 194.5 (179.5 – 210.9) 187.1 (162.6 – 214.8) 0.633
Citrulline, μmol/l 29.4 (26.1 – 33.3) 23.0 (18.6 – 28.4) 0.052
Arginine, μmol/l 45.2 (40.6 – 50.5) 34.8 (28.8 – 42.0) 0.022
Alanine, μmol/l 329.6 (297.1 – 364.8) 337.3 (283.1 – 402.7) 0.814
Taurine, μmol/l 41.3 (37.4 – 45.5) 38.5 (32.6 – 45.6) 0.496
Tyr, μmol/l 58.6 (54.0 – 63.7) 55.6 (48.2 – 64.1) 0.529
Valine, μmol/l 212.8 (198.2 – 228.0) 214.8 (190.5 – 241.5) 0.898
Methionine, μmol/l 22.4 (20.8 – 24.3) 23.3 (20.4 – 26.5) 0.651
Trp, μmol/l 32.1 (28.8 – 35.7) 26.2 (21.8 – 31.5) 0.067
Phe, μmol/l 66.7 (62.2 – 71.4) 74.5 (66.2 – 83.8) 0.122
Isoleucine, μmol/l 59.6 (55.0 – 64.6) 57.7 (50.2 – 66.2) 0.690
Leucine, μmol/l 120.5 (111.4 – 130.6) 123.3 (107.6 – 141.3) 0.783
Ornithine, μmol/l 78.0 (71.0 – 85.5) 67.6 (57.5 – 79.4) 0.146
Values are expressed as means (95% CIs) and are the back-transformed log10 values. Models are adjusted 
for age, gender and Charlson Comorbidity Index.
 Table 3. Mean levels of amino acid ratios and HVA
No delirium (n = 63) Delirium (n = 23) p value
Phe/Tyr ratio 1.14 (1.06 – 1.22) 1.34 (1.19 – 1.51) 0.028
Trp/LNAAs ratio (×100) 6.12 (5.58 – 6.71) 4.90 (4.19 – 5.74) 0.021
Tyr/LNAAs ratio (×100) 11.8 (11.0 – 12.7) 11.0 (9.7 – 12.4) 0.342
Phe/LNAAs ratio (×100) 13.6 (12.7 – 14.7) 15.3 (13.6 – 17.3) 0.122
HVA, nmol/l 93.3 (79.4 – 109.4)a 123.0 (93.3 – 162.6)a 0.098
Values are expressed as means (95% CIs) and are the back-transformed log10 values. Models are adjusted 
for age, gender and Charlson Comorbidity Index.
a One value missing.
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 Discussion 
 In the present study we found disturbed serotonergic neurotransmission and an increased 
status of oxidative stress in patients with delirium when compared to patients without 
delirium.
 As far as we are aware, this is the first delirium study investigating BH 4 status and levels 
of arginine and citrulline in acutely ill elderly hospitalized patients. In order to assess the BH 4 
status, we measured the Phe/Tyr ratio. In patients with delirium we found an increased ratio, 
suggesting a deficiency in the essential cofactor BH 4 for the production of serotonin, dopamine 
and NO. Decreased BH 4 availability has already been found in other neuropsychiatric disorders 
such as Alzheimer’s disease  [20] , Parkinson’s disease  [20] and schizophrenia  [21] . Our finding 
is not in agreement with the results of a previous delirium study which showed that levels of 
BH 4 and Phe/Tyr ratios did not differ between patients with and without delirium  [6] . 
However, that study included a relatively younger group of patients undergoing elective 
cardiac surgery.
 In the present study, serotonergic neurotransmission was investigated with the Trp/
LNAAs ratio and the Phe/Tyr ratio. We found that patients with delirium had a decreased 
Trp/LNAAs ratio, which might suggest reduced serotonin production in the central nervous 
system. This hypothesis is strengthened by the finding that patients with delirium had an 
elevated Phe/Tyr ratio, which might suggest deficiency in the essential cofactor BH 4 in the 
production of serotonin. In previous studies, controversial results have been reported. Several 
studies found a reduced Trp/LNAAs ratio during delirium  [6, 8, 22, 23] , whereas two studies 
reported no difference in this ratio between patients with and without delirium  [24, 25] . The 
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 Fig. 1. Mean levels and corresponding 95% CIs of the Phe/Tyr ratio ( a ), the Trp/LNAAs ratio ( b ), arginine 
( c ) and citrulline ( d ) in patients with and without delirium. 
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study performed by Flacker and Lipsitz  [24] included only patients with mild illnesses not 
requiring hospitalization. Therefore, the findings may not be generalizable to acutely ill 
patients who needed medical care in hospital. The study performed by van der Cammen et al. 
 [25] included delirium patients with Alzheimer’s disease. It might be possible that in those 
patients a disturbance in cholinergic neurotransmission played a more important role in the 
development of delirium than disturbances in other pathophysiological pathways  [26] .
 Furthermore, we found no differences in Phe/LNAAs ratios, Tyr/LNAAs ratios and HVA 
levels between patients with and without delirium, suggesting that dopaminergic neuro-
transmission is not impaired during delirium. The finding that plasma HVA levels are not 
significantly increased in patients with delirium compared to patients without delirium is not 
in agreement with earlier results  [6, 25] . However, those studies were performed in patients 
with Alzheimer’s disease  [25] and patients undergoing cardiac surgery  [6] , and therefore the 
results may not be generalizable. Ramirez-Bermudez et al.  [27] found that cerebrospinal fluid 
HVA levels correlated with psychotic symptoms of delirium (hallucinations and delusions) in 
neurological patients. It might also be possible that we did not find an association between 
the dopaminergic markers and the presence of delirium because we included patients both 
with and without psychotic features.
 In our study, we also found reduced plasma arginine levels and borderline statistically 
significantly reduced citrulline levels in patients with delirium. Considering the cross-sectional 
study design, these findings could mean several things. First, it is possible that patients with 
delirium had a pre-existing arginine deficiency which might have resulted in a reduced 
production of citrulline by NOS ( fig. 2 a). Second, when BH 4 is partially deficient, as our results 
do suggest, some cellular sources of NOS may generate O 2 ∙ – instead of citrulline and NO from 
arginine ( fig. 2 b)  [4, 5] , leading to decreased levels of both arginine and citrulline. If this latter 
scenario is true for delirium, this would also suggest an increased status of oxidative stress, 
since it favors peroxynitrite formation ( fig. 2 b). If peroxynitrite is not scavenged by antioxi-
dants, it may cause oxidative damage to cellular macromolecules  [20, 28] , which has already 
been hypothesized to occur in Alzheimer’s disease  [29] . However, both amino acids have been 
investigated previously by Osse et al.  [6] in patients with delirium after cardiac surgery, but 
they found no differences in arginine and citrulline levels between patients with and without 
delirium. Since they also reported no difference in BH 4 status between patients with and 
without delirium, the results are probable not generalizable to our study.
ba
Arginine
Citrulline NO
BH4
BH4 normal
NOS
Arginine
Citrulline NOO2?–
ONOO–
(peroxynitrite)
Oxidative damage
BH4 ?
BH4 decreased
NOS
 Fig. 2. Schematic presentation of 
the role of BH 4 in the formation
of citrulline, NO and O2∙– by NOS. 
 a Situation in which there is suf-
ficient supply of BH 4 for NOS.
 b Situation in which there is insuf-
ficient supply of BH 4 . Some cellu-
lar sources of NOS will generate 
O 2 ∙ – instead of NO and citrulline. 
Generation of O 2 ∙ –  and NO togeth-
er will lead to the formation of 
peroxynitrite, which may cause 
oxidative damage. 
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 Limitations and Strengths 
 This study has some limitations. First, our findings were obtained in a relatively small 
group of patients; therefore, confirmation in a larger population is recommended. Second, it 
might be speculated that the degree of the patients’ cognitive functioning influenced the mean 
levels of the biochemical parameters  [20] . In this study, we adjusted for the Charlson Comor-
bidity Index, which includes dementia, and our estimates remained statistically significant. 
However, for our additional analysis MMSE scores were not available for all patients; therefore, 
we can neither confirm nor deny that the presence of a comorbid cognitive disturbance, not 
diagnosed as dementia (yet), was a confounding factor. Third, the timing of blood sampling 
might be a factor of significance. It is possible that the levels of biochemical markers are 
dependent on delirium duration and severity or even fluctuate during the day in patients with 
delirium, just like delirium symptoms. In the present study, blood sampling and delirium 
occurred on the same day, but there is a possibility that the patients had no delirium symptoms 
at the moment of blood sampling. This might have influenced our results. Finally, some 
potential participants were not included in the study and this may have resulted in some 
selection bias; however, since this was random and occurred in both patients with and without 
delirium, we think that our results are only minimally influenced by this.
 The present study has several strengths. First, the intensive monitoring of clinical 
symptoms of patients with delirium until discharge and the DSM-IV diagnosis by a geria-
trician makes it less likely that we missed delirium or misdiagnosed symptoms. Second, we 
did not focus on one but on several possible pathways that might lead to delirium as it has 
been suggested that the pathophysiology is multifactorial.
 Conclusion 
 In this study in older, acutely ill hospitalized patients, we found that patients with delirium 
had higher Phe/Tyr ratios, lower Trp/LNAAs ratios and lower levels of arginine and citrulline 
than patients without delirium. These findings might suggest that decreased BH 4 availability, 
disturbed serotonergic neurotransmission and an increased status of oxidative stress may 
have played a role in the pathogenesis of delirium in our patient group. Since as far as we 
know this is the first delirium study investigating BH 4 status and levels of arginine and 
citrulline in acutely ill elderly hospitalized patients, confirmation of our results in a larger, 
comparable population is recommended. Moreover, more research is needed to explore the 
potential differences in the pathophysiology of delirium in patients with and without cognitive 
disorders.
 Acknowledgments 
 We thank all patients who participated in the study. We are also very grateful to Ans 
Voskuilen-Kooijman for her assistance in processing the blood samples and high-perfor-
mance liquid chromatography analyses. This study was supported by a research grant of 
Fund NutsOhra (project number 0902-047).
 Disclosure Statement 
 The authors have no conflicts of interest to declare. 
458Dement Geriatr Cogn Disord Extra 2015;5:450–458
 DOI: 10.1159/000440696 
E X T R A
 Egberts et al.: Disturbed Serotonergic Neurotransmission and Oxidative Stress in 
Elderly Patients with Delirium 
www.karger.com/dee
© 2015 S. Karger AG, Basel
 References 
  1 Witlox J, Eurelings LS, de Jonghe JF, Kalisvaart KJ, Eikelenboom P, van Gool WA: Delirium in elderly patients 
and the risk of postdischarge mortality, institutionalization, and dementia: a meta-analysis. JAMA 2010; 304: 
 443–451. 
  2 Inouye SK, Westendorp RG, Saczynski JS: Delirium in elderly people. Lancet 2014; 383: 911–922. 
  3 Maldonado JR: Neuropathogenesis of delirium: review of current etiologic theories and common pathways. 
Am J Geriatr Psychiatry 2013; 21: 1190–1222. 
  4 Werner ER, Blau N, Thony B: Tetrahydrobiopterin: biochemistry and pathophysiology. Biochem J 2011; 438: 
 397–414. 
  5 Werner ER, Gorren AC, Heller R, Werner-Felmayer G, Mayer B: Tetrahydrobiopterin and nitric oxide: mecha-
nistic and pharmacological aspects. Exp Biol Med (Maywood) 2003; 228: 1291–1302. 
  6 Osse RJ, Fekkes D, Tulen JH, Wierdsma AI, Bogers AJ, van der Mast RC, Hengeveld MW: High preoperative 
plasma neopterin predicts delirium after cardiac surgery in older adults. J Am Geriatr Soc 2012; 60: 661–668. 
  7 van Gool AR, Fekkes D, Kruit WH, Mulder PG, ten Hagen TL, Bannink M, Maes M, Eggermont AM: Serum amino 
acids, biopterin and neopterin during long-term immunotherapy with interferon-alpha in high-risk melanoma 
patients. Psychiatry Res 2003; 119: 125–132. 
  8 van der Mast RC, van den Broek WW, Fekkes D, Pepplinkhuizen L, Habbema JD: Is delirium after cardiac 
surgery related to plasma amino acids and physical condition? J Neuropsychiatry Clin Neurosci 2000; 12: 
 57–63. 
  9 Amin F, Davidson M, Kahn RS, Schmeidler J, Stern R, Knott PJ, Apter S: Assessment of the central dopaminergic 
index of plasma HVA in schizophrenia. Schizophr Bull 1995; 21: 53–66. 
 10 Egberts A, Wijnbeld EH, Fekkes D, van der Ploeg MA, Ziere G, Hooijkaas H, van der Cammen TJ, Mattace-Raso 
FU: Neopterin: a potential biomarker for delirium in elderly patients. Dement Geriatr Cogn Disord 2015; 39: 
 116–124. 
 11 Schuurmans MJ, Shortridge-Baggett LM, Duursma SA: The Delirium Observation Screening scale: a screening 
instrument for delirium. Res Theory Nurs Pract 2003; 17: 31–50. 
 12 American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, text 
revision. Washington, American Psychiatric Association, 2000. 
 13 Folstein MF, Folstein SE, McHugh PR: ‘Mini-mental state’. A practical method for grading the cognitive state of 
patients for the clinician. J Psychiatr Res 1975; 12: 189–198. 
 14 Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longi-
tudinal studies: development and validation. J Chronic Dis 1987; 40: 373–383. 
 15 McDowell I, Newell C: Measuring Health: A Guide to Rating Scales and Questionnaires. New York, Oxford 
University Press, 1996. 
 16 Mahoney FI, Barthel DW: Functional evaluation: the Barthel index. Md State Med J 1965; 14: 61–65. 
 17 Dendukuri N, McCusker J, Belzile E: The Identification of Seniors at Risk screening tool: further evidence of 
concurrent and predictive validity. J Am Geriatr Soc 2004; 52: 290–296. 
 18 Fekkes D: Automated analysis of primary amino acids in plasma by high-performance liquid chromatography. 
Methods Mol Biol 2012; 828: 183–200. 
 19 Fekkes D, Timmerman L, Pepplinkhuizen L: Effects of clomipramine on plasma amino acids and serotonergic 
parameters in panic disorder and depression. Eur Neuropsychopharmacol 1997; 7: 235–239. 
 20 Foxton RH, Land JM, Heales SJ: Tetrahydrobiopterin availability in Parkinson’s and Alzheimer’s disease; 
potential pathogenic mechanisms. Neurochem Res 2007; 32: 751–756. 
 21 Richardson MA, Read LL, Taylor Clelland CL, Reilly MA, Chao HM, Guynn RW, Suckow RF, Clelland JD: Evidence 
for a tetrahydrobiopterin deficit in schizophrenia. Neuropsychobiology 2005; 52: 190–201. 
 22 van der Mast RC, Fekkes D, Moleman P, Pepplinkhuizen L: Is postoperative delirium related to reduced plasma 
tryptophan? Lancet 1991; 338: 851–852. 
 23 Pandharipande PP, Morandi A, Adams JR, Girard TD, Thompson JL, Shintani AK, Ely EW: Plasma tryptophan 
and tyrosine levels are independent risk factors for delirium in critically ill patients. Intensive Care Med 2009; 
 35: 1886–1892. 
 24 Flacker JM, Lipsitz LA: Large neutral amino acid changes and delirium in febrile elderly medical patients. J 
Gerontol A Biol Sci Med Sci 2000; 55:B249–B252; discussion B253–B254. 
 25 van der Cammen TJ, Tiemeier H, Engelhart MJ, Fekkes D: Abnormal neurotransmitter metabolite levels in 
Alzheimer patients with a delirium. Int J Geriatr Psychiatry 2006; 21: 838–843. 
 26 Hshieh TT, Fong TG, Marcantonio ER, Inouye SK: Cholinergic deficiency hypothesis in delirium: a synthesis of 
current evidence. J Gerontol A Biol Sci Med Sci 2008; 63: 764–772. 
 27 Ramirez-Bermudez J, Ruiz-Chow A, Perez-Neri I, Soto-Hernandez JL, Flores-Hernandez R, Nente F, Montes S, 
Rios C: Cerebrospinal fluid homovanillic acid is correlated to psychotic features in neurological patients with 
delirium. Gen Hosp Psychiatry 2008; 30: 337–343. 
 28 Reiter RJ, Tan DX, Burkhardt S: Reactive oxygen and nitrogen species and cellular and organismal decline: 
amelioration with melatonin. Mech Ageing Dev 2002; 123: 1007–1019. 
 29 Smith MA, Richey Harris PL, Sayre LM, Beckman JS, Perry G: Widespread peroxynitrite-mediated damage in 
Alzheimer’s disease. J Neurosci 1997; 17: 2653–2657. 
 
